Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
North Carolina reaches $590 million PFAS settlement with Chemours, DuPont
2+ day, 12+ hour ago (613+ words) WILMINGTON, NC (WWAY) — North Carolina Attorney General Jeff Jackson and Department of Environmental Quality Secretary Reid Wilson announced Thursday a $590 million settlement involving the state, 11 local governments, DuPont and Chemours over PFAS contamination. State officials call it the largest total…...
Chemours to Pay $455 Million for Fayetteville Works Contamination
2+ day, 17+ hour ago (1162+ words) North Carolina and a handful of local governments agreed to settle with Chemours over its pollution in the eastern part of the state, the parties announced on Thursday. The company will pay the state and 11 entities near its Fayetteville Works…...
J&J wins FDA nod for Imaavy in rare blood disorder
2+ week, 4+ day ago (409+ words) Patients with a rare and potentially life-threatening blood disorder now have an FDA-approved treatment for the first time. The US regulator has cleared Johnson & Johnson’s Imaavy (nipocalimab) for warm autoimmune haemolytic anaemia, or wAIHA, in patients aged 12 and older who…...
J&J???s Imaavy secures expanded US approval in rare blood disorder
2+ week, 4+ day ago (275+ words) The FDA approval marks another successful step in J&J’s aim of achieving $5bn in peak sales for the drug. The US Food and Drug Administration (FDA) has expanded the label indication of Johnson & Johnson’s (J&J) Imaavy (nipocalimab-aahu) to treat…...
FDA clears J&J's Imaavy as first treatment for rare blood disorder
2+ week, 5+ day ago (14+ words) FirstWord Pharma...
Counterpoint: Precision cuts both ways in PFAS debate
3+ week, 2+ day ago (181+ words) Kenneth P. Moritsugu’s recent commentary (“Minnesota’s PFAS law risks cutting off patients from needed medical devices,” Aug. 12) calls for “precision” in how we regulate PFAS in medical devices. I agree entirely, which is why the argument deserves a closer look than…...